Snjezana Mijatovic

Dr. Snjezana Mijatovic

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
MSMihailo Stjepanovic
Mihailo Stjepanovic
Aleksandra BaracAleksandra Barac
Aleksandra Barac
AGAleksa Golubovic
Aleksa Golubovic
FMFilip Markovic
Filip Markovic
SMSnjezana Mijatovic
Snjezana Mijatovic
JJJelena Jankovic
Jelena Jankovic
Asthma is a complex respiratory condition characterized by airway inflammation and hyper-responsiveness, and poses a significant global health burden, affecting millions worldwide. Its origins lie in interactions between genetic, environmental, and host factors. While typically manageable, asthma can lead to severe exacerbations and complications if left untreated. The association between asthma and fungal infections, particularly with Aspergillus species, has garnered attention due to its impact on disease severity and management. We aim to provide a comprehensive overview of this association focusing on its various clinical presentations, risk factors, diagnostic approaches, and treatment strategies. Allergic bronchopulmonary aspergillosis (ABPA) emerges as a prevalent form of aspergillosis in asthmatic individuals, presenting challenges in both diagnosis and management. We discuss the evolving diagnostic criteria for ABPA, emphasizing the importance of clinical suspicion, radiological findings, serological tests, and pulmonary function tests. Moreover, we address the therapeutic interventions, review the roles of systemic glucocorticoids, antifungal agents, and emerging novel therapeutic agents. Early detection and intervention in fungal infections in asthma patients, particularly ABPA, are essential to mitigate exacerbations, improve symptom control, and prevent severe complications. This review underscores the necessity for heightened awareness and proactive management of fungal infections in the context of asthma, aiming to enhance patient care and quality of life.

30 September 2024 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
SBSlobodan Belić
Slobodan Belić
AIAndjelka Ivanovic
Andjelka Ivanovic
ATAleksandra Todorovic
Aleksandra Todorovic
NMNikola Marić
Nikola Marić
SMSandra Milic
Sandra Milic
JJJelena Jankovic
Jelena Jankovic
Introduction: Since COVID-19 first surfaced in 2019, it has seriously threatened public health. The most prevalent symptoms are respiratory ones. This study aimed to present the correlation between the severity of the clinical presentation of the disease and the results of respiratory function tests conducted within 6 months after hospital discharge. Methodology: This retrospective study included 99 patients with confirmed SARS-CoV-2 virus infection. Of all patients 24.2% had accentuated bronchovascular pattern, 9.1% had unilateral, and 29.3% had bilateral pneumonia. In comparison, 35.4% patients had diffuse changes, which were described as acute respiratory distress syndrome (ARDS) on computed tomography (CT). Results: Patients with unilateral, bilateral pneumonia or diffuse lung damage had significantly lower forced vital capacity (FVC) values. They were treated with non-invasive mechanical ventilation (NIV) or invasive mechanical ventilation (MV) and had lower FVC values (0.039). A negative, weak correlation existed between CT findings during the infection and Diffusing capacity for carbon monoxide (DLCO) measured after the infection (0.003). A negative, weak correlation was found between oxygen therapy, the use of NIV, and MV findings during the infection with DLCO. A negative correlation was noted between leukocyte values during the infection and forced expiratory volume in the first second (FEV1) and FVC after the infection. Conclusions: Patients with COVID-19 infection who need oxygen support and MV continue to suffer from loss of respiratory function after the resolution of COVID-19 infection. These findings highlight the negative predictive value of pulmonary tests in the long-term follow-up for the development of PC-ILD as well as decreased pulmonary capacity.

18 March 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
MSMihailo Stjepanovic
Mihailo Stjepanovic
SMSnjezana Mijatovic
Snjezana Mijatovic
NNNikola Nikolic
Nikola Nikolic
NMNikola Marić
Nikola Marić
GSGoran Stevanovic
Goran Stevanovic
Aleksandra BaracAleksandra Barac
Aleksandra Barac
Background: Tuberculosis (TB) remains a leading cause of mortality worldwide, particularly in low- and middle-income countries. The rise of multidrug-resistant TB (MDR-TB) poses significant challenges to global health. This study reviews the experience of the largest pulmonology center in Serbia, a country with low MDR-TB incidence, focusing on TB prevalence, resistance detection, and treatment strategies between 2012 and 2021. Methods: We retrospectively analyzed a total of 1239 patients who were diagnosed and treated for TB in the period from 2012 to 2021 at University Clinical Center of Serbia. Results: Drug resistance was identified in 21 patients (1.7%), with the highest resistance to rifampicin (1.4%) and isoniazid (1.3%). Pyrazinamide and streptomycin resistance were detected in only a few cases. Patients with resistant TB were younger on average, though the difference was not statistically significant (46.4 ± 19.1 vs. 53.6 ± 18.4, p = 0.079). Prior TB history was more frequent in the resistant group, almost reaching statistical significance (4 vs. 82, p = 0.052). Conclusions: These findings underscore the critical importance of sustained surveillance, particularly of latent and drug-resistant TB forms, in alignment with the World Health Organization’s (WHO) TB control strategy to preserve Serbia’s low-incidence status. Moreover, given Serbia’s strategic location on a major migration route, there is an elevated risk of new TB cases emerging and potential shifts in TB-drug-resistance patterns developing in the future.

Verified
Journal Article
Open access
PDF file
NDNatasa Djurdjevic
Natasa Djurdjevic
MPMarija Dusanovic Pjevic
Marija Dusanovic Pjevic
MSMihailo Stjepanovic
Mihailo Stjepanovic
NCNikola Colic
Nikola Colic
SDSanja Dimic-Janjic
Sanja Dimic-Janjic
MGMilka Grk
Milka Grk
Progressive pulmonary fibrosis (PPF) comprises interstitial lung diseases characterized by progressive fibrosis and lung function decline. Nintedanib slows disease progression by inhibiting FGFR, VEGFR, and PDGFR signaling, but treatment response varies among patients. We investigated whether VEGFR2, PDGFRB, and TGFB1 gene variants are associated with nintedanib treatment outcomes, including changes in pulmonary function, diffusing capacity and adverse effects. This prospective study included 75 patients with PPF diagnosed according to ATS/ERS/JRS/ALAT criteria and treated with nintedanib at the Clinic of Pulmonology, University Clinical Center of Serbia. Spirometry and diffusing capacity were assessed at baseline and after 6 and 12 months. Genotyping of VEGFR2 rs2071559 and rs1870377; PDGFRB rs2302273, rs2229562, and rs246395; and TGFB1 rs1800470 was performed using TaqMan® assays. Carriers of the PDGFRB rs2302273 A allele more frequently experienced gastrointestinal adverse events (45.2% vs. 20.5%; p = 0.022; OR 3.2, 95% CI 1.156–8.866) and diarrhea (38.7% vs. 15.9%; p = 0.026; OR 3.3, 95% CI 1.129–9.869). Patients with the PDGFRB rs246395 TT genotype more frequently had a ≥15% decline in DLCO after one year (46% vs. 22%; p = 0.038; OR 3.0, 95% CI 1.045–8.394). No significant associations were observed for the analyzed VEGFR2 or TGFB1 variants. These findings suggest that PDGFRB variants may be associated with nintedanib treatment outcomes, although confirmation in larger cohorts is needed.